Denver, Colorado- Markets are digesting a wave of corporate developments spanning biotech innovation, AI infrastructure, edge computing and digital asset tokenization, with several companies delivering headline-grabbing updates that could shape sector narratives in 2026.
Totaligent Boldly Expands into Biologics Infrastructure
Totaligent (OTCID:TGNT) announced the execution of a binding Letter of Intent to acquire key assets and talent from Aetherium Medical (www.aetheriummedical.com) in a non-cash acqui-hire transaction. The deal includes Aetherium’s intellectual property, dual-track regulatory strategy, business plan and network relationships, with assets to be housed in a newly formed subsidiary, Aetherium Medical LLC.
The strategic focus is clear: building infrastructure that bridges next-generation biologic therapies with global patient access through compliant medical tourism channels. Under the LOI, Ivan Klarich will be appointed Managing Director of the subsidiary, and the Aetherium team will receive restricted preferred stock initially representing 10% of Totaligent’s outstanding equity, with additional milestone-based equity contemplated.
CEO Edward C. DeFeudis described the move as “a pivotal step in our strategic evolution toward high-growth opportunities at the intersection of advanced biologics, medical tourism, and data-driven commercialization.” The transaction is targeted to close in early March 2026, subject to due diligence and definitive agreements.
For investors, the development signals Totaligent’s ambition to move beyond AI-powered marketing into infrastructure supporting high-growth biotech commercialization pathways.
Fastly Delivers Record Quarter as AI Becomes a Tailwind
Fastly (NASDAQ:FSLY) reported record fourth-quarter and full-year 2025 results, underscoring a turnaround narrative gaining traction in the edge cloud space.
Fourth-quarter revenue rose 23% year over year to $172.6 million, with GAAP gross margin expanding to 61.4% from 53.4% a year earlier. Non-GAAP operating income swung to $21.2 million from a loss in the prior-year period. Remaining Performance Obligations (RPO) surged 55% year over year to $353.8 million, reflecting strengthening forward demand visibility.
For the full year, revenue reached $624.0 million, up 15% year over year, while non-GAAP net income turned positive at $19.7 million compared to a loss in 2024.
CEO Kip Compton noted the company achieved record revenue, gross margin and operating profit, adding that AI is expected to serve as an “increasing tailwind” in 2026. Guidance calls for full-year 2026 revenue between $700 million and $720 million, with projected non-GAAP operating income of $50 million to $60 million.
With improving margins, rising enterprise customer counts and strengthening retention (LTM net retention rate of 110%), Fastly appears positioned to benefit from growing AI-driven traffic and security workloads at the edge.
Novocure Secures Landmark FDA Approval in Pancreatic Cancer
Novocure (NASDAQ:NVCR) announced U.S. Food and Drug Administration approval of Optune Pax® for the treatment of locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel, the first new FDA-approved treatment for this indication in nearly 30 years.
In the Phase 3 PANOVA-3 trial, Optune Pax demonstrated a statistically significant improvement in median overall survival in the intent-to-treat population (16.2 months vs. 14.2 months; HR 0.82, p=0.039) and extended time to pain progression by 6.1 months compared to chemotherapy alone.
CEO Frank Leonard called the approval “a proud moment for Novocure,” emphasizing the device’s differentiated biophysical mechanism using Tumor Treating Fields (TTFields). The wearable system was generally well tolerated, with no new safety signals observed.
Given the historically limited progress in pancreatic cancer, the approval could mark a meaningful commercial and clinical inflection point for Novocure.
NuScale Leverages AI to Optimize Nuclear Fuel Management
NuScale Power Corporation (NYSE:SMR) is partnering with Oak Ridge National Laboratory under the U.S. Department of Energy’s GAIN initiative to explore AI-enabled optimization of nuclear fuel management across its 12-module reactor configuration.
The collaboration aims to use artificial intelligence and machine learning to improve fuel efficiency across multiple small modular reactors at a single site, potentially enhancing cost economics beyond what is achievable in traditional single-reactor plants.
CEO John Hopkins said the partnership will use “cutting-edge computational science to create even more energy efficient fuel management solutions.” As energy demand accelerates globally, particularly from AI and data center growth, small modular reactor innovation remains a closely watched theme.
BridgeBio Reports Breakthrough Phase 3 Results in Achondroplasia
BridgeBio Pharma (NASDAQ:BBIO) reported positive topline data from its Phase 3 PROPEL 3 study of oral infigratinib in children with achondroplasia.
The study met its primary endpoint, demonstrating a statistically significant improvement in annualized height velocity versus placebo (LS mean treatment difference +1.74 cm/year; p<0.0001). Notably, infigratinib also achieved the first statistically significant improvement in body proportionality in a randomized trial for achondroplasia among children under eight.
The therapy was well tolerated, with no serious adverse events related to the study drug. BridgeBio plans NDA and MAA submissions in the second half of 2026. Infigratinib holds FDA Breakthrough Therapy Designation for achondroplasia.
With limited non-invasive treatment options available, the data could position infigratinib as a differentiated oral alternative in a rare disease market with high unmet need.
VerifyMe and Open World Target RWA Tokenization Opportunity
VerifyMe (NASDAQ:VRME) and blockchain infrastructure platform Open World announced the signing of a merger agreement aimed at forming a Nasdaq-listed institutional-grade real-world asset (RWA) tokenization company.
The combined entity is expected to focus on regulated digital asset infrastructure, enterprise compliance frameworks and cross-jurisdictional tokenization initiatives, building on Open World’s previously disclosed Saudi Arabia RWA Center of Excellence.
The transaction is subject to shareholder approvals and customary closing conditions, with regulatory filings anticipated by the second quarter of 2026.
As regulatory clarity evolves in digital assets, institutional-grade tokenization infrastructure remains a developing but closely watched theme.
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7MN) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7MN delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how they can help accelerate your company’s visibility and valuation trajectory.
24/7 MARKET NEWS, INC (247) Disclaimer and Disclosure
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by one or more featured companies for providing ongoing TGNT market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://go.247marketnews.com/tgnt-disclosure/ for further TGNT and 247marketnews.com disclosure information.